On Thursday, December 12, Alphamab Oncology listed on the Main Board of The Stock Exchange of Hong Kong Limited, raising HK$1.8 billion ($230 million). Alphamab Oncology is a leading clinical-stage biopharmaceutical company in China with a fully integrated proprietary biologics platform in biospecifics and protein engineering. Four drug candidates in the company’s pipeline have advanced to clinical development phase, including a PD-L1 antibody and two bispecific antibodies PD-L1/CTLA4 and HER2. Wilson Sonsini Goodrich & Rosati represented Alphamab Oncology on related intellectual property matters.

The Wilson Sonsini team advising on the IP matters related to the offering includes senior of counsel Karen Wong, partner Peter Eng, associate Richard Wang, and patent agents Brandon Tavshanjian and Nicolas Tiee.